EyePoint Pharmaceuticals Statistics Share Statistics EyePoint Pharmaceuticals has 68.93M
shares outstanding. The number of shares has increased by 28.58%
in one year.
Shares Outstanding 68.93M Shares Change (YoY) 28.58% Shares Change (QoQ) 0.12% Owned by Institutions (%) 99.99% Shares Floating 60.27M Failed to Deliver (FTD) Shares 41 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 7.69M, so 11.15% of the outstanding
shares have been sold short.
Short Interest 7.69M Short % of Shares Out 11.15% Short % of Float 13.36% Short Ratio (days to cover) 10.24
Valuation Ratios The PE ratio is -3.2 and the forward
PE ratio is -3.93.
EyePoint Pharmaceuticals's PEG ratio is
-0.12.
PE Ratio -3.2 Forward PE -3.93 PS Ratio 9.69 Forward PS 64.5 PB Ratio 1.25 P/FCF Ratio -3.22 PEG Ratio -0.12
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for EyePoint Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.81,
with a Debt / Equity ratio of 0.06.
Current Ratio 7.81 Quick Ratio 7.77 Debt / Equity 0.06 Debt / EBITDA -0.17 Debt / FCF -0.17 Interest Coverage -10418.14
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $262.26K Profits Per Employee $-793.15K Employee Count 165 Asset Turnover 0.1 Inventory Turnover 1.61
Taxes Income Tax 90K Effective Tax Rate -0.07%
Stock Price Statistics The stock price has increased by 75.78% in the
last 52 weeks. The beta is 1.95, so EyePoint Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.95 52-Week Price Change 75.78% 50-Day Moving Average 10.68 200-Day Moving Average 8.03 Relative Strength Index (RSI) 77.25 Average Volume (20 Days) 705,209
Income Statement In the last 12 months, EyePoint Pharmaceuticals had revenue of 43.27M
and earned -130.87M
in profits. Earnings per share was -2.32.
Revenue 43.27M Gross Profit 39.56M Operating Income -145.85M Net Income -130.87M EBITDA -129.23M EBIT -130.77M Earnings Per Share (EPS) -2.32
Full Income Statement Balance Sheet The company has 99.7M in cash and 21.86M in
debt, giving a net cash position of 77.85M.
Cash & Cash Equivalents 99.7M Total Debt 21.86M Net Cash 77.85M Retained Earnings -873.02M Total Assets 301.15M Working Capital 232.08M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -126.23M
and capital expenditures -4.05M, giving a free cash flow of -130.28M.
Operating Cash Flow -126.23M Capital Expenditures -4.05M Free Cash Flow -130.28M FCF Per Share -2.31
Full Cash Flow Statement Margins Gross margin is 91.42%, with operating and profit margins of -337.06% and -302.43%.
Gross Margin 91.42% Operating Margin -337.06% Pretax Margin -302.22% Profit Margin -302.43% EBITDA Margin -298.63% EBIT Margin -337.06% FCF Margin -301.06%
Dividends & Yields EYPT does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for EYPT is $26.5,
which is 89.2% higher than the current price. The consensus rating is "Buy".
Price Target $26.5 Price Target Difference 89.2% Analyst Consensus Buy Analyst Count 6
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Dec 9, 2020. It was a
backward
split with a ratio of 1:10.
Last Split Date Dec 9, 2020 Split Type backward Split Ratio 1:10
Scores Altman Z-Score 3.39 Piotroski F-Score 3
